William Guyer - 04 Mar 2026 Form 4 Insider Report for CORCEPT THERAPEUTICS INC (CORT)

Role
Chief Development Officer
Signature
/s/ Joseph Douglas Lyon, as attorney-in-fact for William Guyer.
Issuer symbol
CORT
Transactions as of
04 Mar 2026
Net transactions value
-$296,346
Form type
4
Filing time
06 Mar 2026, 16:30:18 UTC
Previous filing
04 Mar 2026
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Guyer William Chief Development Officer C/O CORCEPT THERAPEUTICS INCORPORATED, 101 REDWOOD SHORES PARKWAY, REDWOOD CITY /s/ Joseph Douglas Lyon, as attorney-in-fact for William Guyer. 06 Mar 2026 0001879013

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CORT Common Stock Options Exercise +8,233 +369% $21.65* 10,464 04 Mar 2026 Direct F1
transaction CORT Common Stock Sale $296,346 -8,233 -79% $35.99 2,231 04 Mar 2026 Direct F1, F2, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CORT Stock Option (right to buy) Options Exercise -8,233 -3.6% $0.000000* 221,767 04 Mar 2026 Common Stock 8,233 $21.65 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 Includes 224 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025 and 498 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 2, 2026. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements.
F2 This transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person on November 27, 2024 in effect at the time of this transaction.
F3 Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $35.97 to $36.05 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
F4 Fully exercisable.

Remarks:

The power of attorney under which this form was signed is on file with the Commission.